Get the Stockscreener App
1.05
1.94%
0.02
Enlivex Therapeutics Ltd stock is traded at $1.05, with a volume of 884.86K.
It is up +1.94% in the last 24 hours and down -11.02% over the past month.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
See More
Previous Close:
$1.03
Open:
$1.01
24h Volume:
884.86K
Relative Volume:
2.06
Market Cap:
$24.83M
Revenue:
-
Net Income/Loss:
$-14.33M
P/E Ratio:
-1.5909
EPS:
-0.66
Net Cash Flow:
$-13.21M
1W Performance:
-42.31%
1M Performance:
-11.02%
6M Performance:
+5.00%
1Y Performance:
-18.60%
1-Day Range:
$0.98
$1.05
1-Week Range:
$0.98
$1.75
52-Week Range:
$0.8101
$2.10
Enlivex Therapeutics Ltd Stock (ENLV) Company Profile
Name
Enlivex Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare ENLV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Therapeutics Ltd
|
1.05 | 29.81M | 0 | -14.33M | -13.21M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-21 | Reiterated | H.C. Wainwright | Buy |
Enlivex Therapeutics Ltd Stock (ENLV) Latest News
Enlivex Therapeutics Ltd. Could See a Relief Rally From SupportJuly 2025 Outlook & Reliable Breakout Stock Forecasts - newsyoung.net
How moving averages guide Enlivex Therapeutics Ltd. tradingJuly 2025 Weekly Recap & Verified Momentum Stock Ideas - Newser
Using Python tools to backtest Enlivex Therapeutics Ltd. strategiesQuarterly Profit Report & Fast Entry Momentum Trade Alerts - Newser
Is Enlivex Therapeutics Ltd. stock bottoming out2025 Technical Patterns & Free Community Supported Trade Ideas - Newser
Using data filters to optimize entry into Enlivex Therapeutics Ltd.2025 Support & Resistance & Growth Focused Stock Pick Reports - Newser
Quantitative breakdown of Enlivex Therapeutics Ltd. recent moveTrade Risk Assessment & Daily Chart Pattern Signals - Newser
Real time pattern detection on Enlivex Therapeutics Ltd. stockQuarterly Profit Report & High Conviction Buy Zone Alerts - Newser
Published on: 2025-08-20 00:58:54 - Newser
What high frequency data says about Enlivex Therapeutics Ltd.2025 Market Outlook & Smart Money Movement Tracker - Newser
How to manage a losing position in Enlivex Therapeutics Ltd.Quarterly Portfolio Summary & AI Based Buy and Sell Signals - Newser
Is Enlivex Therapeutics Ltd. showing signs of accumulationEarnings Growth Report & Safe Capital Growth Tips - Newser
What earnings revisions data tells us about Enlivex Therapeutics Ltd.Bear Alert & Community Trade Idea Sharing - Newser
Enlivex Therapeutics shares rise 1.90% after-hours following a special call event. - AInvest
Enlivex Therapeutics shares fall 14.40% intraday after a special call with RedChip Companies. - AInvest
What indicators show strength in Enlivex Therapeutics Ltd.Market Risk Analysis & Safe Entry Zone Tips - Newser
Risk vs reward if holding onto Enlivex Therapeutics Ltd.July 2025 Macro Moves & Intraday High Probability Alerts - Newser
Enlivex Therapeutics (NASDAQ:ENLV) Receives Buy Rating from D. Boral Capital - Defense World
Enlivex advances lead cell therapy to Phase IIb in osteoarthritis - Yahoo Finance
Key metrics from Enlivex Therapeutics Ltd.’s quarterly dataTrade Entry Report & AI Forecasted Entry/Exit Points - Newser
Is Enlivex Therapeutics Ltd. building a consolidation base2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - Newser
Support Zone Holds Steady for Enlivex Therapeutics Ltd. After Dip2025 Support & Resistance & Stepwise Entry and Exit Trade Signals - newsimpact.co.kr
Transcript : Enlivex Therapeutics Ltd.Special Call - MarketScreener
Enlivex Therapeutics (ENLV) Receives Continued 'Buy' Rating from D. Boral Capital | ENLV Stock News - GuruFocus
Enlivex Stocks Rises On Encouraging Phase IIa Data for Allocetra in Knee Osteoarthritis - MSN
Enlivex Announces Promising Phase IIa Results for Allocetra in Knee Osteoarthritis - TipRanks
Enlivex Announces Positive Topline Data From Multi-Country, Rand - GuruFocus
Enlivex stock soars after positive knee osteoarthritis trial data By Investing.com - Investing.com Nigeria
Enlivex stock soars after positive knee osteoarthritis trial data - Investing.com
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis - The Manila Times
Enlivex Therapeutics Reveals Positive Three-Month Data from ENX-CL-05-001 Trial Highlighting Allocetra™ Efficacy in Knee Osteoarthritis Patients - Quiver Quantitative
72% Pain Reduction: Enlivex's Allocetra Demonstrates Breakthrough Results in Knee Osteoarthritis Trial - Stock Titan
Is a relief rally coming for Enlivex Therapeutics Ltd. holders2025 Winners & Losers & AI Driven Stock Reports - Newser
Enlivex Therapeutics Ltd. stock trendline breakdownQuarterly Portfolio Report & Reliable Price Breakout Alerts - Newser
How to use Fibonacci retracement on Allarity Therapeutics Inc.July 2025 PostEarnings & Free Real-Time Volume Trigger Notifications - Newser
Is Enlivex Therapeutics Ltd.’s ROE strong enoughJuly 2025 Review & Technical Entry and Exit Tips - thegnnews.com
Applying big data sentiment scoring on Enlivex Therapeutics Ltd.2025 Trading Recap & Risk Controlled Stock Alerts - Newser
How Enlivex Therapeutics Ltd. stock performs during market volatilityWall Street Watch & Stock Portfolio Risk Control - Newser
Using Bollinger Bands to evaluate Enlivex Therapeutics Ltd.Entry Point & Precise Buy Zone Identification - Newser
What candlestick patterns are forming on Enlivex Therapeutics Ltd.2025 Institutional Moves & AI Powered Market Trend Analysis - Newser
Key resistance and support levels for Enlivex Therapeutics Ltd.2025 Market WrapUp & Daily Profit Maximizing Trade Tips - Newser
Enlivex Therapeutics Ltd Stock (ENLV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):